Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia
Journal of Pharmaceutical Health Services Research · 06.02.2013 · 4 (1) · 29-39
DOI: 10.1111/jphs.12004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Health Services Research, online erschienen am 07.01.2013. Verfasst von Jessica Panish und 3 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Scientific Affairs, LLC Titusville, New Jersey, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Assess association between adherence and persistence with second-generation oral antipsychotics (SGOAs), psychiatric-related relapse and healthcare utilization among patients with schizophrenia experiencing two or more psychiatric-related relapses.
Methods
A retrospective analysis of the US Medicaid Multi-State Database for 2004–2008. Patients with schizophrenia (aged 18–64) with two or more psychiatric-related relapses within 1 year after SGOA initiation were selected. Associations between a dichotomous measure of adherence and persistence with SGOAs and psychiatric-related relapse and healthcare utilization were assessed using unadjusted and covariate-adjusted regression models. No adjustment was made for multiplicity. Key findings Study cohort consisted of 3714 patients with mean age of 42.6 years. Overall, 45% of patients were adherent and 50% persistent with SGOAs. Unadjusted and covariate-adjusted analysis results suggested the 12-month psychiatric-related relapse rate was lower among adherent/persistent patients versus non-adherent patients (unadjusted mean: 3.85 versus 4.13; P < 0.001; covariate-adjusted incident rate ratio (IRR): 0.90; 95% confidence interval (CI): 0.86–0.94) and non-persistent patients (unadjusted mean: 3.81 versus 4.21; P < 0.001; covariate-adjusted IRR: 0.88; 95%CI: 0.84–0.92). Compared with non-persistent patients, persistent patients had significantly lower rates of all-cause inpatient admissions (IRR: 0.87; 95%CI: 0.82–0.93) and emergency department visits (IRR: 0.78; 95%CI: 0.73–0.85).
Conclusions
Although SGOAs have proven efficacy in lowering the rate of psychiatric-related relapses, lower adherence and persistence rates may be an inhibiting factor in achieving optimal benefits from SGOAs. Future research is needed to assess whether newer antipsychotics with less-frequent dosing may improve adherence among patients with schizophrenia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Janssen Scientific Affairs, LLC Titusville, New Jersey, USA.
Zitieren
APA
Panish, J., Karve, S., Candrilli, S. D., & Dirani, R. (2013). Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. Journal of Pharmaceutical Health Services Research, 4(1), 29-39. https://doi.org/10.1111/jphs.12004
Vancouver
Panish J, Karve S, Candrilli SD, Dirani R. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. Journal of Pharmaceutical Health Services Research. 2013;4(1):29-39. doi:10.1111/jphs.12004
BibTeX
@article{Panish2013,
author = {Panish, Jessica and Karve, Sudeep and Candrilli, Sean D and Dirani, Riad},
title = {Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia},
journal = {Journal of Pharmaceutical Health Services Research},
year = {2013},
volume = {4},
number = {1},
pages = {29--39},
doi = {10.1111/jphs.12004}
}
EUVIMED